Carpenter, Katherine J.
Valfort, Aurore-Cecile
Steinauer, Nick
Chatterjee, Arindam http://orcid.org/0000-0002-2990-6389
Abuirqeba, Suomia
Majidi, Shabnam
Sengupta, Monideepa
Di Paolo, Richard J.
Shornick, Laurie P.
Zhang, Jinsong
Flaveny, Colin A. http://orcid.org/0000-0002-5391-715X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (1 R01 CA234105-01A1)
U.S. Department of Defense (W81XWH-16-1-0333)
Article History
Received: 26 August 2019
Accepted: 5 December 2019
First Online: 20 December 2019
Competing interests
: The authors K.J.C., A.C.V., N.S., S.A., S.M., M.S., R.J.D., L.P.S. and J.Z. declare no competing interests. The authors A.C. and C.A.F. are inventors on an awarded international patent application filed by Saint Louis University that covers the use of LXR inverse agonists as treatments for cancer (International Publication number: WO 2017/223514 A1).